Abstract
Despite extensive research focusing on development of therapeutics for traumatic brain injury (TBI) and success in preclinical trials, numerous phase 3 clinical trials have been failed mainly due to heterogeneity of TBI and poor diagnostic and outcome prediction tools currently available to make a proper assessment of type of injury and patient status. Current TBI diagnostics is mainly centered on neurological assessment (e.g., Glasgow Coma Scale) and neuroimaging, which can be subjective, not sensitive, and/or often not available.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call